Methods and compositions for treating type 2 diabetes and related conditions
OwnerUdaya Sankar Devanaboyinainventor
Life of this patent
Estimating the term…
Abstract
In some embodiments, there are provided methods and compositions for treating, preventing, or delaying the onset of type 2 diabetes and related disorders. The methods comprise administering a sustained release composition comprising a peroxisome proliferator-activated receptor (PPAR) agonist subcutaneously in a localized area of the subject. Slow release of the PPAR agonist in situ enhances the metabolic activity of subcutaneous adipose tissue, resulting in an increased ability of the tissue to clear excess glucose and lipid from the blood stream, while minimizing adverse side-effects of the agonist.
Claims20
A method for treating a mammalian subject with a condition selected from the group consisting of type 2 diabetes, hyperlipidemia, and cardiovascular disease, wherein said method comprises:
- administering a sustained release composition into a subcutaneous space in a localized area of said subject;
- wherein said composition comprises a peroxisome proliferator-activated receptor (PPAR) agonist;
- wherein said composition releases said agonist directly into said subcutaneous space;
- wherein subcutaneous adipose tissue in said space is exposed in situ to a therapeutically effective amount of said agonist;
- and,
- whereby systemic exposure in said subject to said agonist is minimized.
A method for preventing or treating type 2 diabetes and related disorders in a subject, the method comprising:
- exposing subcutaneous adipose tissue of said subject in situ to a peroxisome proliferator-activated receptor agonist at a sufficient level and over a sufficient duration to activate brown adipocyte-like differentiation in said adipose tissue, wherein the differentiated subcutaneous adipose tissue has increased energy expenditure, wherein substantially no adverse effect due to said agonist is detectable in said subject.
A method comprising:
- exposing subcutaneous adipose tissue in situ in a subject to a peroxisome proliferator-activated receptor agonist, wherein said exposing is sufficient to increase and maintain an increase in the quantity of brite adipocytes in said tissue.
Dependencies are inferred from the claim text.